Anzeige
Mehr »
Login
Donnerstag, 23.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
InnoCan Pharma: Jetzt in die Doppel-Chance investieren?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XF0S | ISIN: US00972D1054 | Ticker-Symbol: AX9
Tradegate
22.05.24
17:21 Uhr
1,041 Euro
+0,020
+1,96 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
AKEBIA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
AKEBIA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,0121,03016:49
1,0121,03016:49

Aktuelle News zur AKEBIA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.05.Earnings call: Akebia reports positive outlook for Vafseo launch8
09.05.Akebia Therapeutics, Inc. - 10-Q, Quarterly Report3
09.05.Akebia Therapeutics, Inc. - 8-K, Current Report3
09.05.Akebia Therapeutics, Inc.: Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights96Akebia to host conference call at 8:00 a.m. ET on May 9 Vafseo® (vadadustat) tablets FDA approved on March 27, 2024 Vafseo launch activities underway with availability expected in January 2025 Auryxia®...
► Artikel lesen
08.05.Akebia Q1 2024 Earnings Preview4
01.05.Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)75CAMBRIDGE, Mass., May 1, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted...
► Artikel lesen
23.04.Akebia Therapeutics, Inc. - 8-K, Current Report3
16.04.Akebia Therapeutics, Inc. - 8-K, Current Report5
03.04.Akebia Therapeutics Surges on FDA Approval for Anemia Treatment22
02.04.Akebia Therapeutics, Inc.: Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)117CAMBRIDGE, Mass., April 2, 2024 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,...
► Artikel lesen
31.03.Akebia Recovers From Rejection to Win FDA Approval for Anemia Drug13
28.03.FDA approves Akebia anemia pill, two years after rejection16
28.03.FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia7
28.03.Akebia joins GSK in US market for oral CKD anaemia drugs10
28.03.US STOCKS Crypto stocks, Akebia Therapeutics, Sprinklr5
28.03.Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD5
28.03.Akebia's Vafseo gains FDA approval for anaemia due to CKD4
28.03.Akebia stock jumps as FDA clears renal anemia therapy5
28.03.Akebia Therapeutics rises after US FDA approves anemia drug6
28.03.US FDA approves Akebia's anemia drug14
Seite:  Weiter >>
41 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1